{"nct_id":"NCT03264989","title":"Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)","status":"COMPLETED","status_verified_date":"2024-10","start_date":"2017-12-19","start_date_type":"ACTUAL","primary_completion_date":"2023-06-26","primary_completion_date_type":"ACTUAL","completion_date":"2023-06-26","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["NVS"]}